CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial Survival prospects of treatment naïve patients with Eisenmenger: a systematic review of the literature and report of own experience Functional and morphological assessment of side branch after left main coronary artery bifurcation stenting with cross-over technique Sex-Based Outcomes in Patients With a High Bleeding Risk After Percutaneous Coronary Intervention and 1-Month Dual Antiplatelet Therapy: A Secondary Analysis of the LEADERS FREE Randomized Clinical Trial Pulmonary hypertension related to congenital heart disease: a call for action Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial ACCF/AHA 2009 expert consensus document on pulmonary hypertension a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association

Clinical Trial2014 Dec 4;371(23):2155-66

JOURNAL:N Engl J Med. Article Link

Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents

Mauri L, Kereiakes DJ, DAPT Study Investigators. Keywords: DAPT duration; coronary artery disease; DES; platelet aggregation; inhibitors; stents; thrombosis

FULL TEXT PDF